CompaniesGyroscope Therapeutics

Gyroscope Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (5)
View all

Total Trials

5

As Lead Sponsor

5

As Collaborator

0

Total Enrollment

717

By Phase

PHASE2: 3PHASE1/PHASE2: 1

By Status

TERMINATED: 4ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
NCT03846193
NCT03894020
NCT04437368
NCT04566445
NCT05481827
Hover over trial bars to see details

Recent Trials

NCT05481827Lead Sponsor
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
PHASE2Enrolling by invitation
225 participants
Started: Jul 12, 2022 · Completed: Jun 2, 2028
NCT04566445Lead Sponsor
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
PHASE2Terminated
255 participants
Started: Sep 28, 2020 · Completed: Jun 10, 2024
NCT04437368Lead Sponsor
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
PHASE2Terminated
98 participants
Started: Apr 26, 2019 · Completed: Apr 5, 2024
NCT03894020Lead Sponsor
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
N/ATerminated
83 participants
Started: Jan 8, 2019 · Completed: Mar 25, 2024
NCT03846193Lead Sponsor
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
PHASE1/PHASE2Terminated
56 participants
Started: Dec 17, 2018 · Completed: Jun 25, 2024
Funding History (3)
DRS/A
Apr 2, 2021
Filing
DRS/A
Feb 22, 2021
Filing
DRS
Jan 11, 2021
Filing
Related Companies
Novartis
acquired